+

WO2001060375A8 - Use of 7alpha-hydroxy-estradiol, 7alpha-hydroxy-dehydroepiandrosterone and 7alpha-hydroxy-pregnenolone derivatives for treating acute cellular degeneration - Google Patents

Use of 7alpha-hydroxy-estradiol, 7alpha-hydroxy-dehydroepiandrosterone and 7alpha-hydroxy-pregnenolone derivatives for treating acute cellular degeneration

Info

Publication number
WO2001060375A8
WO2001060375A8 PCT/GB2001/000627 GB0100627W WO0160375A8 WO 2001060375 A8 WO2001060375 A8 WO 2001060375A8 GB 0100627 W GB0100627 W GB 0100627W WO 0160375 A8 WO0160375 A8 WO 0160375A8
Authority
WO
WIPO (PCT)
Prior art keywords
hydroxy
7alpha
dehydroepiandrosterone
estradiol
treating acute
Prior art date
Application number
PCT/GB2001/000627
Other languages
French (fr)
Other versions
WO2001060375A2 (en
WO2001060375A3 (en
Inventor
Richard Frank Lathe
Jonathan Robert Seckl
Keith Frank Martin
Ernst Arne Wulfert
Original Assignee
Hunter Fleming Ltd
Univ Edinburgh
Btg Int Ltd
Richard Frank Lathe
Jonathan Robert Seckl
Keith Frank Martin
Ernst Arne Wulfert
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hunter Fleming Ltd, Univ Edinburgh, Btg Int Ltd, Richard Frank Lathe, Jonathan Robert Seckl, Keith Frank Martin, Ernst Arne Wulfert filed Critical Hunter Fleming Ltd
Priority to CA002398706A priority Critical patent/CA2398706A1/en
Priority to AU3385601A priority patent/AU3385601A/en
Priority to EP01905886A priority patent/EP1307205B1/en
Priority to DE60127683T priority patent/DE60127683D1/en
Priority to AU2001233856A priority patent/AU2001233856B2/en
Priority to JP2001559471A priority patent/JP2003522794A/en
Publication of WO2001060375A2 publication Critical patent/WO2001060375A2/en
Publication of WO2001060375A8 publication Critical patent/WO2001060375A8/en
Publication of WO2001060375A3 publication Critical patent/WO2001060375A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

A method is provided for treating a patient in need of therapy for acute neuronal degeneration due to metabolic compromise of central or peripheral nervous system cells comprising administering to that patient a therapeutically effective amount of a 7α-hydroxy substituted steroid selected from 7α-hydroxy-derivatives of estradiols, dehydroepiandrosterones and pregnenolones, and metabolic precursors thereof. Use of such compounds for manufacture of medicaments and neuroprotective compositions are also provided.
PCT/GB2001/000627 2000-02-15 2001-02-15 Use of 7alpha-hydroxy-estradiol, 7alpha-hydroxy-dehydroepiandrosterone and 7alpha-hydroxy-pregnenolone derivatives for treating acute cellular degeneration WO2001060375A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
CA002398706A CA2398706A1 (en) 2000-02-15 2001-02-15 Cytoprotective steroids (ii)
AU3385601A AU3385601A (en) 2000-02-15 2001-02-15 Cytoprotective steroids (ii)
EP01905886A EP1307205B1 (en) 2000-02-15 2001-02-15 Use of 7alpha-hydroxy-estradiol, 7alpha-hydroxy-dehydroepiandrosterone and 7alpha-hydroxy-pregnenolone derivatives for treating acute cellular degeneration
DE60127683T DE60127683D1 (en) 2000-02-15 2001-02-15 USE OF 7ALPHA-HYDROXY-ESTRADIOL, 7ALPHA-HYDROXY-DEHYDROEPIANDROSTERONE AND 7ALPHA-HYDROXY-PREGNENOLON DERIVATIVES FOR THE TREATMENT OF ACUTE CELLULAR DEGENERATION
AU2001233856A AU2001233856B2 (en) 2000-02-15 2001-02-15 Use of 7Alpha-hydroxy-estradiol, 7Alpha-hydroxy-dehydroepiandrosterone and 7alpha-hydroxy-pregnenolone derivatives for treating acute cellular degeneration
JP2001559471A JP2003522794A (en) 2000-02-15 2001-02-15 Cytoprotective steroid (II)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0003524.6A GB0003524D0 (en) 2000-02-15 2000-02-15 Cytoprotective steroids (II)
GB0003524.6 2000-02-15

Publications (3)

Publication Number Publication Date
WO2001060375A2 WO2001060375A2 (en) 2001-08-23
WO2001060375A8 true WO2001060375A8 (en) 2001-11-15
WO2001060375A3 WO2001060375A3 (en) 2002-04-04

Family

ID=9885683

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2001/000627 WO2001060375A2 (en) 2000-02-15 2001-02-15 Use of 7alpha-hydroxy-estradiol, 7alpha-hydroxy-dehydroepiandrosterone and 7alpha-hydroxy-pregnenolone derivatives for treating acute cellular degeneration

Country Status (9)

Country Link
US (1) US20030092692A1 (en)
EP (1) EP1307205B1 (en)
JP (1) JP2003522794A (en)
AT (1) ATE358489T1 (en)
AU (2) AU2001233856B2 (en)
CA (1) CA2398706A1 (en)
DE (1) DE60127683D1 (en)
GB (1) GB0003524D0 (en)
WO (1) WO2001060375A2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2363983A (en) 2000-06-29 2002-01-16 Hunter Fleming Ltd Protection against neuronal damage using 7-hydroxyepiandrosterone
GB2363984A (en) * 2000-06-29 2002-01-16 Hunter Fleming Ltd Protection against neuronal damage using 3-hydroxy-7 -hydroxy steroids and 3-oxo-7 -hydroxy steroids
GB2378898A (en) * 2001-08-14 2003-02-26 Hunter Fleming Ltd Prophylactic and therapeutic use of hydroxysteroids
US7910755B2 (en) 2004-09-29 2011-03-22 Harbor Biosciences, Inc. Stem cell expansion and uses
US8124598B2 (en) 2006-09-14 2012-02-28 Sharon Sageman 7-keto DHEA for psychiatric use
EP2147673A1 (en) 2006-11-30 2010-01-27 Hunter-Fleming Limited Modulation of prostaglandin/cyclooxygenase metabolic pathways
US20100160274A1 (en) * 2007-09-07 2010-06-24 Sharon Sageman 7-KETO DHEA for Psychiatric Use
CZ301216B6 (en) * 2008-07-10 2009-12-09 Ústav organické chemie a biochemie Akademie ved CR, v. v. i. Pregnane anionic compounds, process for preparing thereof and their use
CU20110244A7 (en) 2011-12-27 2013-08-29 Ct De Investigación Y Desarrollo De Medicamentos Cidem SPI-ESTEROID SYSTEMS WITH NEUROACTIVE AND ANTI-INFLAMMATORY EFFECTS

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
YU243975A (en) * 1974-10-14 1982-06-30 Schering Ag Process for obtaining 7-hydroxyestradiols
US5292730A (en) * 1990-08-29 1994-03-08 Humanetics Corporation Modulation of immune system with Δ5-androstenes
FR2696934B1 (en) * 1992-10-20 1995-06-02 Conservatoire Nal Arts Metiers Derivatives of natural hydroxyl 3B steroids having properties of triggering and stimulating immunity, composition containing them and process for obtaining them.
US5846963A (en) * 1995-06-07 1998-12-08 University Of Utah Research Foundation Methods for preventing progressive tissue necrosis, reperfusion injury, bacterial translocation and adult respiratory distress syndrome
US5554601A (en) * 1993-11-05 1996-09-10 University Of Florida Methods for neuroprotection
JP4313435B2 (en) * 1995-07-24 2009-08-12 トラスティーズ オブ ボストン ユニバーシティー Inhibition of NMDA receptor activity by pregnenolone sulfate derivatives
CA2250874A1 (en) * 1996-04-09 1997-10-16 Btg International Limited Use of 7 alpha-substituted steroids to treat neuropsychiatric, immune or endocrine disorders
FR2760362B1 (en) * 1997-03-10 2000-08-11 Vitasterol COSMETIC OR DERMATOLOGICAL USE OF 7-HYDROXYL STEROIDS

Also Published As

Publication number Publication date
US20030092692A1 (en) 2003-05-15
DE60127683D1 (en) 2007-05-16
WO2001060375A2 (en) 2001-08-23
AU2001233856B2 (en) 2006-05-25
EP1307205A2 (en) 2003-05-07
ATE358489T1 (en) 2007-04-15
JP2003522794A (en) 2003-07-29
EP1307205B1 (en) 2007-04-04
GB0003524D0 (en) 2000-04-05
WO2001060375A3 (en) 2002-04-04
CA2398706A1 (en) 2001-08-23
AU3385601A (en) 2001-08-27

Similar Documents

Publication Publication Date Title
WO2002022132A8 (en) Novel topical oestroprogestational compositions with systemic effect
AU7445901A (en) Pharmaceutical compositions comprising cannabidiol derivatives
MXPA05006940A (en) Therapeutic formulations for the treatment of beta-amyloid related diseases.
IL195723A (en) Use of p53 inhibitors for the preparation of medicament
WO2005058233A3 (en) Methods for treatment of acute pancreatitis
SG161307A1 (en) Oligoribonucleotides and methods of use thereof for treatment of alopecia, acute renal failure and other diseases
EP1249238A8 (en) Topical pharmaceutical composition comprising bethanechol
WO2004105702A3 (en) Foamable pharmaceutical compositions and methods for treating a disorder
CA2301057A1 (en) A method of administering liposomal encapsulated taxane
IL211288A (en) Pharmaceutical vaginal composition for reducing or relieving uterine dysrhythmia and use of an anti-dysrhythmic treating agent in the manufacture of medicaments for vaginal administration in reducing or relieving uterine dysrhythmia
HUP0101693A3 (en) Use of steroidal sapogenins and their derivatives for producing pharmaceutical compositions for the treatment of alzheimeirs disease
PL309604A1 (en) Pharmaceutical composition for treating nicotin dependence
WO2001030802A3 (en) Therapeutic treatments comprising administration of certain steroids for blood cell deficiencies
JP2004526758A5 (en)
HUP0101901A3 (en) Pharmaceutical composition for combined therapeutic treatment of refractory depression and combined treating process
WO2001060375A8 (en) Use of 7alpha-hydroxy-estradiol, 7alpha-hydroxy-dehydroepiandrosterone and 7alpha-hydroxy-pregnenolone derivatives for treating acute cellular degeneration
WO1999022722A3 (en) Use of macrolides for the treatment of cancer and macular degeneration
WO2001024783A3 (en) Use of (+)-tramadol, o-demethyltramadol or (+)-o-demethyltramadol, o-desmethyl-n-mono-desmethyl-tramadol or (+)-o-desmethyl-n-mono-desmethyl-tramadol for treating urinary incontinence
AU3092397A (en) Use of p-aminophenol derivatives for the preparation of pharmaceutical compositions useful in the treatment of neurodegenerative diseases
CA2268305A1 (en) Use of an h+, k+-atpase inhibitor in the treatment of nasal polyps
AU6528400A (en) Triple drug therapy for the treatment of narcotic and alcohol withdrawal symptoms
WO1999033450A3 (en) Pharmaceutical composition containing sibutramine and orlistat
WO2000008007A3 (en) Cyclopentabenzofuran derivatives and their use
WO2005094899A8 (en) Clusterin antisense therapy for treatment of cancer
HUP0101005A2 (en) Medicament for preventing and/or treating a mammary carcinoma, containing a steroidal aromatase inhibitor

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: C1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: C1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2398706

Country of ref document: CA

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2001 559471

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 2001233856

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2001905886

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 10203880

Country of ref document: US

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 2001905886

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 2001905886

Country of ref document: EP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载